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INTRODUCTION 
 World Health Organisation has defined a drug as “a substance or 
product that is used or intended to be used to modify or explore 
physiological system or pathological state of the recipient”1. 
 Adverse drug reaction is defined by WHO as “a response to a drug 
that is noxious, unintended and undesired and occurs at doses used in 
man for modification of physiological function2”. ADRs affect upto 7% of 
the general population and constitute upto 8% of  hospital admissions3. 
 Cutaneous ADRs are among the more commonly observed adverse 
reactions to medications. Among the various morphological drug reaction 
patterns encountered, Fixed Drug Reactions account for upto one third of 
cases. According to many Indian studies, Fixed drug eruption is the most 
common cutaneous adverse drug reaction pattern, constituting 25-40% of 
cases12,13. In the western world, it is next only to maculopapular rash as 
the common cause of CADR14,15,16. Several studies analysing the 
epidemiological, pathophysiological, pharmacological and clinical 
aspects of FDE are available in literature. Though clinically less severe, 
FDE causes cosmetic embarrassment in many patients.   
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REVIEW OF LITERATURE 
           Adverse Drug Reactions are categorised into predictable (Type A) 
and unpredictable (Type B) reactions.  
 Predictable reactions are usually dose dependent, related to the 
known pharmacological actions of the drug and occur in otherwise 
healthy subjects. They account for 80% of the drug reactions. 
Unpredictable reactions are dose independent, unrelated to the 
pharmacological actions of the drug and occur only in susceptible 
subjects2,4. 
TYPE A – PREDICTABLE REACTIONS TYPE B – UNPREDICTABLE REACTIONS 
NONIMMUNOLOGICAL REACTIONS : 
- OVERDOSAGE 
- SIDE EFFECTS 
- FACULTATIVE EFFECTS 
- DELAYED TOXICITY 
- DRUG REACTIONS 
- METABOLIC ALTERATIONS 
- EXACERBATION OF DISEASE 
- DRUG INDUCED CHROMOSOMAL 
DAMAGE 
- TERATOGENICITY 
¾ NONIMMUNOLOGICAL REACTIONS : 
- DRUG INTOLERANCE 
- DRUG IDIOSYNCRASY 
¾ IMMUNOLOGICAL :  DRUG ALLERGY 
(GELL AND COOMBS SYSTEM OF 
HYPERSENSITIVTY REACTIONS) 
• TYPE I  -  IMMEDIATE REACTIONS,  
MEDIATED BY  IgE ANTIBODIES(Abs) 
• TYPE II  -  CYTOTOXIC REACTIONS, 
MEDIATED BY DRUG SPECIFIC Abs.  
• TYPE III -   IMMUNE COMPLEX 
MEDIATED REACTIONS 
• TYPE IV  -  DELAYED TYPE 
HYPERSENSITIVITY REACTIONS                    
 
 Type IV reactions can be subdivided into 4 Categories5 involving 
activation and recruitment of 
  
3
- Monocytes (Type IVa) 
- Eosinophils (Type IVb) 
- CD4+/CD8+ cells (Type IVc) 
- Neutrophils (Type IVd) 
 There is also a recently proposed addition to the drug 
hypersensitivity reactions, where a drug noncovalently binds to a TCR 
without prior sensitisation, analogous to the concept of superantigens6. 
 Numerous cutaneous eruptions have been attributed to drug 
induced allergic reactions  which include 
Type I reactions    : Urticaria , Angioedema, Anaphylaxis 
Type II reactions      : Sedormid purpura, Thrombocytopenic 
purpura 
Type III reactions  : Serum sickness, Vasculitis, Arthus reaction, 
Rarely urticaria and anaphylaxis 
Type IV Reactions   : Exanthems, Fixed drug eruptions, Erythema 
multiforme, Steven Johnson Syndrome, 
Toxic Epidermal Necrolysis. 
 
FIXED DRUG ERUPTION : 
 Fixed drug eruption represents an interesting cutaneous adverse 
drug reaction characterised by solitary or multiple, well circumscribed, 
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erythematous or dusky red patches, that may evolve into edematous 
plaques or bullae, with pruritus or burning sensation and characteristically 
recurs at the same site or sites, each time the drug is administered .With 
each exposure , the number of involved sites may increase and the lesions 
usually resolve with post inflammatory hyper pigmentation7. 
HISTORY :             
            In 1889, Bourns described a series of sharply demarcated 
hyperpigmented lesions on the lips and tongue of a patient who had 
recently ingested 20 g of antipyrine8. A few years later , Brocq coined  
the term ‘eruption erythemato-pigmentee fixe’ from which the term  
Fixed Drug Eruption is derived9. 
EPIDEMIOLOGY : 
          The incidence of FDE varies form 2.5% to 22%10,11. All ages are 
vulnerable. FDE has been reported in infancy121 as well as in individuals 
as old as 87 yrs40. Most cases are in the age group of 20-40 years.  
 According to a study conducted in Pakistan, the mean age at 
presentation was 30.4 yrs in males and 31.3 years in females40,72. 
According to few recent studies, the ratio of male to female affected was 
almost equal. In earlier studies a male preponderance was noted10,11.  
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Mode of exposure : 
 Ingestion – commonest19  
 Intravenous                                                                                  
 Sublingual  
 Intradermal  
 Per-rectal 
 Inhalants18 
 Sexual transmission20 
PATHOMECHANISM : 
1. Genetic predisposition : 
 Familial cases of FDE have been reported across the world21.  
Recent reports indicated a significant association between FDE and HLA-
class I antigens . A few associations are given below 
 Fepraxone       - HLA B22 
 Cotrimoxazole - HLA – A30 B13 CW6  
 Naproxen        - HLA A1 & B5121,22 
2. Immunology : 
 Fixed drug eruption is a delayed cytotoxic T-cell mediated 
hypersensitivity reaction . It is thought to result mainly from autoimmune 
destruction of epidermal keratinocytes by T-cells, triggered by the 
offending drug23.  
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 Immunohistochemical characterisation of FDE lesions reveals the 
existence of significant numbers of CD8+Tcells in  the basal or  
suprabasal location over a prolonged period of time even after clinical 
resolution23,24. These findings have led to hypothesize that these 
epidermal T-cells residing in FDE lesions, upon activation by a relevant 
antigen, could be involved in the disease process and may play a role in 
preserving the memory function of FDE. The intraepidermal CD8+ 
memory T cells established in resting lesional skin of FDE, on activation, 
produce large amounts of IFN. They transiently acquire a Natural killer 
cell like phenotype and express cytotoxic granules. They have high levels 
of perforins and are capable of  producing IFN and TNFα26,29. According 
to one study, intraepidermal CD8+Tcells in FDE lesions use a very 
limited T-cell repertoire consisting of the Vα and Vβ gene families, when 
compared to the peripheral blood lymphocytes by quantitative PCR  
analysis27. This indicates that following reexposure to the causative drug, 
there is some expansion or preferential migration of epidermal T-cells 
that recognize a restricted set of antigens expressed within the epidermis. 
FACTORS CONTRIBUTING TO PERSISTENCE: 
 The cytokines released by the CD8+ T-cells trigger the increased 
production of IL-15 by lesional keratinocytes, which in turn is a ligand 
for IL-2Rβ chain expressed by CD8+ T-cells26.28. There is also increased 
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expression of ICAM1 by lesional keratinocytes24. These two factors 
contribute to the survival of CD8+ T-cells within the lesional skin and 
result in repeated occurrence of FDE lesion at the same site. 
MECHANISM OF RESOLUTION OF ACUTE EPISODES: 
 There is accumulating evidence that the CD4+ regulatory T cells 
play a role in the control of immune pathology. A significant number of 
CD25+,CD4+ reg T cells are recruited to the lesional skin 24 hours after 
challenge with the offending drug. The increased expression of IL-10 by 
these reg T-cells might suppress the effector memory function of CD8+T-
cells in active FDE lesions bringing about clinical resolution30,31. 
HISTOPATHOLOGY : 
 Established lesions show a lichenoid reaction pattern. The 
histological changes resemble those of EMF and TEN. The inflammatory 
infltrate tends to obscure the dermoepidermal interface as in EMF. The 
infiltrates extend into mid and upper epidermis, producing death of 
keratinocytes above the basal layer.  
 Scattered necrotic keratinocytes with eosinophilic cytoplasm and 
pyknotic nuclei ( referred to as Civatte bodies) are frequently seen in the 
epidermis and represent apoptosis. The frequent hydropic degeneration of 
basal cell layer leads to pigment incontinence, which is characterised by 
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the presence of melanin within macrophages in the upper dermis32. The 
degenerated  keratinocytes show less shrinkage than in lichen planus33. In 
severe lesion ,a subepidermal cleft or bulla may form32.  
 Fixed drug eruptions cannot be confidently distinguished  from 
EMF and TEN. However the deeper extension of the infiltrate, the  
presence  of few neutrophils and more prominent melanin incontinence, 
differentiate FDE from EMF32.  
 Based on one study, it appears that a very early lesion may show 
epidermal spongiosis, dermal edema and neutrophil microabcess and 
numerous eosinophils in the demis. These features usually disappear after 
several days, although some eosinophils persist34. 
 In the eczematous variant, spongiotic changes may be seen. 
Vasculitis is another pattern encountered35. In the nonpigmenting variant, 
these is mild perivascular and interstitial mixed inflammatory infiltrate in 
the dermis36. 
ELECTRON MICROSCOPY: 
 There is prominent clumping of tonofilaments in the cytoplasm 
with bright eosinophilic cytoplasm especially in the basal and supra basal 
layers. The accumulation of tonofilaments represents a response by 
keratinocytes to sublethal injury (or) some other stimulus37. 
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 The pigmentary incontinence develops when  
a) macrophages invade the epidermis and phagocytize the 
necrotic keratinocytes together with their melanosomes   
b) the necrotic  macrophages return to dermis where they digest 
all the cellular remnants except for melanosomes38.  
           The intraepidermal lymphocytes are largely CD8+ T cells, whereas 
the dermal perivascular and interstitial lymphocytes are predominantly 
CD4+ cells. 
CLINICAL FEATURES : 
 The initial episode usually occurs few weeks after the intake of 
drug. The degree of sensitisation of an individual to a particular drug 
determines the first development of FDE. Once sensitisation occurs, the 
subsequent episodes develop within 30 minutes to 8 hrs4,39.  
 Fixed drug eruptions classically manifest as sharply circumscribed 
round to oval patches, with violaceous or dusky erythema, which heal 
with hyperpigmentation in 6-10 days39.The hyperpigmentation may 
persist for months to years . Cross reaction may occur with structurally 
similar drugs. The acute episode may be asymptomatic or associated with 
local symptoms like itching, burning or pain. Sometimes generalised 
itching may occur. Constitutional symptoms like fever, myalgia, 
arthralgia, nausea and vomiting have been described. Other symptoms 
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like abdominal cramps , anorexia , dysuria , disorientation and confusion 
may also occur40. Rarely FDE can manifest as pruritus ani or pruritus 
vulvae.  
 Koebnerisation was demonstrated in one study41.Dermographism 
has been demonstrated over FDE lesions43. The lesions of FDE may 
increase in number and size with each subsequent episode, resulting in 
progressively bigger patches .The union of lesions may produce a 
polycyclic or band like pattern .Sometimes pruritus and burning may be 
the only manifestation of reactivation in a old patch40.  
SITE OF INVOLVEMENT : 
 The classical FDE mainly involves the limbs , hands, feet42,46 and 
Genitalia44 .Oral cavity45 ,lips46, perioral, periorbital,  perianal areas40 and 
conjunctivae31 may also be involved.The lesions may be localised or 
generalised. These have also been reports of bilateral symmetrical 
distribution of lesions18. 
DRUGS IMPLICATED IN FDE :  
Antibacterials  
Ampicillin, amoxicillin53,54               Nitroimidazoles61 
Ceftriaxone56 Penicillins53 
Clindamycin40 Rifampicin118 
Dapsone62 Sulphonamides 
(Cotrimoxazole)51,52 
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Fluoroquinolones58,59 Tetracyclines57 
Erythromycin, clarithromycin60 Others - Arsenicals and 
Mercurials42 
 
Antivirals  
Acyclovir63                                                                 Foscarnet64 
Antifungals  
Clioquinol71 Itraconazole70 
Griseofulvin67 Nystatin 
Ketoconazole66 Terbinafine69 
Fluconazole68  
 
Antimalarials72 
Sulfadoxine and pyrimethamine 
Antiparasitic  
Albendazole40                                   Pyrantel palmoate40 
Levamisole73 
Anti-inflammatory drugs 
Aspirin74                                           Indomethacin40  
Acetaminophen75                              Mefenamic acid40 
Celecoxib76                                       Naproxen78 
Oxyphenbutazone45                          Nimesulide79  
Diclofenac sodium40                         Oxyphenbutazone  
Ibuprofen77                                       Piroxicam49 
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Antihistamine  
Cetrizine80                                         Hydroxyzine84 
Cyclizine83                                        Levocetrizine 
Dimenhydrinate85                             Loratidine81  
Diphenhydramine82  
Anticonvulsants 
Carbamazepine87                               Phenytoin87 
Lamotrigine88                                    Sodium valproate87 
Anti hypertensives  
ACE inhibitors89                               Calcium channel blockers89 
β blockers – Atenolol89 
Anticancer drugs  
Docitaxel90                                     
Paclitaxel90 
Antipsycotic drugs –            Barbiturates, Benzodiazepines89   
Opioids alkaloids91  
Miscellaneous  
Allopurinol40 Multivitamins103  
Anthralin Omeprazole89 
Belladonna40 Ondansetron146 
Butazolidine72   Quinine102 
Chloral hydrate Papaverine104 
Chlormezanone40 Phenolphthalein105 
Clopidogrel96 Phenylpropanolamine106 
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Colchicine90 Pseudoephedrine106 
Cyproterone acetate94                         Sorafenib107 
Dipyrone46 Sodium fluorescein89 
Food substitutes & flavours94      Sulfasalazine / sulfaguanide89 
Finasteride Sympatholytics89 
Flecainide95 Thiacetazone50 
Infuenza vaccine97                              Ticlopidine108 
Interferon98    Tonic water- quinine109 
Iopamide99 Tranexamic acid110 
Lactose in botulinum toxin100  
Methaqualone101  
Metamizole40  
Mouth wash – Chlorhexidine102  
 
 In addition fixed food eruption have also been described to tinned 
Asparagus, cashew nuts, lentils and strawberries111,112. 
DRUG SPECIFIC SITES OF INVOLVEMENT :  
FDE on lips : 
        Certain drugs like naproxen and oxicams are the main inducers of 
FDE on lips. Others drugs reported include cotrimoxazole, ciprofloxacin, 
erythromycin and prochlorperazine49,50. 
Oral FDE : 
        Oral FDE can occur due to drugs like tetracyclines, 
oxyphenbutazone and Cotrimoxazole45.  
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Genital FDE :  
        Isolated genital FDE can occur with tetracylines, cotrimoxazole and 
ampicillin44. There are reports of erosive vulvitis occurring following 
paracetamol113. 
Other sites : 
 Dipyrone, a pyrazolone derivative & Nonsteroidal 
Antiinflammaory Drug(NSAID) is reported to cause FDE on trunk & 
extremities. Dipyrone, aspirin and parcetamol spare lips, genitalia and 
trunk50. 
Other rare reports :                
 Rare reports of familial cases, nonpigmenting FDE, linear FDE, 
wandering FDE and solitary plaques over cheeks have been ascribed to 
cotrimoxazole48. A rare report of naproxen induced FDE with peculiar 
unilateral breast involvement is available in literature115.Constitutional 
symptoms are commonly observed with levamisole and thiacetazone50. 
OTHER MORPHOLOGICAL PATTERNS : 
1) Bullous FDE: 
 Bullous FDE  usually produces multifocal lesions characterised by 
multiple, large, sharply defined deeply red patches and blisters, 
displaying a bilaterally symmetrical distribution, with a predilection for 
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extremities, genitalia and intertriginous sites116-118. It occurs abruptly and 
continues to increase in size and number even after cessation of the 
offending drug. Mucosal sites are usually spared and constitutional 
symptoms are mild121,122. Recovery is complete without sequelae. There 
are reports of  bullous FDEs occuring with drugs like cetrizine123, 
flecainide95, fluconazole68, fluoroquinolones58, metronidazole120, 
naproxen124, paracetamol75, paclitaxel90, rifampicin118, influenza 
vaccination97 etc.  
 Nonpigmenting bullous FDE has been reported with 
pseudoephedrine106. Widespread bullous FDE may mimic SJS & TEN 
clinically. It is important to distinguish bullous FDE from the other two 
CADRs, as it carries a good prognosis. A histopathological examination 
may help in differentiation between FDE, SJS and TEN. Epidermal 
changes cannot be differentiated and vary from a few scattered necrotic 
keratinocytes to full thickness epidermal necrosis. Presence of 
intraepidermal vesiculation with ballooning degeneration and 
keratinocyte necrosis makes the diagnosis of FDE more likely. Close 
examination of the dermis is helpful for differentiation. In SJS and TEN, 
the infiltrate is lymphohistiocytic and tends to be located solely around 
superficial plexus. In FDE, in addition, a mixed inflammatory infiltrate 
containing neutrophils and eosinophils in addition is noted around  
superficial and deep plexuses125-127.  
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Non pigmenting FDE (NPFDE) : 
 The concept of NPFDE was first proposed by Abramovitz and 
Noun in 1937128. This variant has been associated with drugs like 
pseudoephedrine106, phenylpropanolamine106, tetrahydrozoline129, 
piroxicam130 ,radioopaque contrast medium iothalmate131, ,diflunisal132, 
indomethacin, arsphenamine, thiopental133 paracetamol134,intraarticular 
triamcinolone acetonide135 and eperisone hydrochloride136.    
 Pseudoephedrine has been the commonest cause of NPFDE and 
forms an important constituent of many Japanese and Chinese herbal 
medicines (Ephedra hebra especially)65.  
 NPFDE poses a clinical challenge, as the replicate nature of 
eruption exists without the physical clues that is recogonisable with the 
pigmenting forms of FDE. NPFDE has been characterised by multiple 
symmetrically distributed lesions  
 The site of hypersensitivity response is considered to be dermal 
according to a few studies. In a study done to determine the factors 
responsible for the lack of pigmentation before challenge, the NPFDE 
lesions are characterised by  large number of CD8+ intraepidermal T-
cells and paucity of melanocytes, when compared with pigmented FDE 
lesion.  
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 Very high levels of serum IL-10 were noted after clinical 
challenge. NPFDE with epidermal involvement may be an abortive form 
of SJS/TEN in which progression to TEN can be prevented by IL- 10137. 
3) Erythema multiforme like FDE127 
4) Linear FDE – Trimethoprim, Cephazoline.  
 The linearity may be related to the distribution of the dermatoses, 
Blaschko’s lines, skin tension lines and anatomical structures138. 
5) Wandering FDE139 
6) Morilbilliform/Scarlatiniform FDE 
7)  SJS / TEN like FDE 
8) Urticaria like FDE41  
9) LP like FDE 
10) Paronychia 
12) Chelitis  
13) Psoriasisform FDE 
14) Housewife’s eczema like FDE 
15) Melasma like FDE 
16) DLE like FDE 
17) Erythema annulare centrifugum like FDE 
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18) Pemphigus vulgaris like FDE 
19) Chilblain like FDE  
20) PR like FDE  
21) Vulval /perianal melanosis /periorbital40  
Complication and prognosis : 
Local - Secondary infection  
 - Residual hyperpigmentation  
Prognosis is good. No deaths have been reported so far. 
CROSS REACTIVITY : 
 Cross reaction can occur to drugs with similar structures. The cross  
reactivity of drugs within a pharmacological group is not an all or none 
phenomenon. Cross reactivity is commonly observed among the 
following group of drugs. 
• Among paraamino group of compounds in sulphonamides 
induced FDE140 
• Among nitroimidazole group of drugs61 
• Among azoles – esp fluconazole & itraconazole141 
• Among fluoroquinolones142 
• Among tetracycline group of drugs143 
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 Knowledge about cross reactivity may be quite useful for selecting 
alternative drugs.  
POLYSENSITIVITY : 
 It is the occurrence of FDE as a reaction to multiple drugs with 
chemically unrelated structures in the same patients. The lesions may 
occur on identical or separate sites. The incidence is 0.2-0.8%148. 
Reported cases of polysensitivity :  
• Metamizole and saridon 
• Metamizole and penicillin G 
• Oxyphenbutaxone and Phenobarbital 
• Metamizole and tetracycline143 
• Ampicillin,ibuprofen and acetyl salicyclic acid144 
• Phenytoin,sodium valproate and carbamazepine145 
• Paracetamol and tropisetron – ondansetron146 
• Doxycycline and metronidazole147 
• Cotrimoxazole and tenoxicam148 
 Shiohara and Kokaji  claimed that drugs and foods containing 
nonspecific mastcell degranulators such as acetyl salicylic acid and 
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bacterial toxins or physical stimuli such as friction can induce rapid local 
release of cytokines from mastcells like TNFα. This provides a localised 
initiating stimulus for residing epidermal T-cells, thus producing 
reactivation of FDE lesions149.  
DIAGNOSIS OF FDE :- 
 An exact history and description of clinical manifestation is 
mandatory. History taking should include details of all drugs taken by the 
patient before the reaction.  It is also important to know the dates the 
treatment was begun and stopped ,the  mode of drug administration, the 
prescribed dosage and the disease for which it was prescribed.             
Many algorithms are available to establish the causality of a particular 
drug in drug eruptions  like those devised by Jones150, Naranjo151, Kramer 
et al152 and WHO. 
WHO UMC Criteria for causality assessment : 
Certain 
 Event or laboratory test abnormality, with plausible time 
relationship to drug intake 
 Cannot be explained by disease or other drugs 
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 Response to withdrawal plausible (pharmacologically, 
pathologically) 
 Event definitive pharmacologically or phenomenologically (i.e. an  
objective and specific medical disorder or a known 
pharmacological phenomenon). 
 Rechallenge satisfactory, if necessary 
Probable /Likely 
 Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
 Unlikely to be attributed to disease or other drugs 
 Response to withdrawal clinically reasonable 
 Rechallenge not required 
Possible 
 Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
 Could also be explained by disease or other drugs 
 Information on drug withdrawal may be lacking or unclear 
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Unlikely 
 Event or laboratory test abnormality, with a time to drug intake that 
makes a relationship improbable (but not impossible) 
 Disease or other drugs provide plausible explanations 
Conditional /Unclassified 
 Event or laboratory test abnormality 
 More data for proper assessment needed, or 
 Additional data under examination 
Unassessable/Unclassifiable 
 Report suggesting an adverse reaction 
 Cannot be judged because information is insufficient or 
contradictory 
 Data cannot be supplemented or verified153 
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DRUG TESTS AVAILABLE TO DETERMINE THE CAUSE OF 
FDE:        
IN VIVO TESTS INVITRO TESTS 
• Drug skin tests 
¾ Patch test / Repeat 
application test 
¾ Skin prick test 
¾ Intradermal skin test154 
• Challenge test/provocation 
test157 
¾ Lymphocyte transformation test 
¾ CD69 upregulation test 
¾ Measurement of drug induced 
cytokine production from 
peripheral blood mononuclear 
cells158 
 
 The diagnosis of drug hypersensitivity reaction continues to be a 
challenge, as the optimal skin test concentrations for several drugs are yet 
to be determined. The few in vitro tests that are available are not 
validated158. 
 A negative topical provocation test result does not exclude the 
responsibility of a drug in the causation of FDE . However these tests 
have a high degree of specificity155,158. Therefore in case of doubt, the 
potential drug should be withdrawn from further pharmacotherapy, or 
alternatively, a drug provocation test has to prove the clinical relevance 
and results. But the ethical issues related to drug provocation tests and the 
risk benefit ratio should be taken into account before performing the 
tests156. 
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Patch test :- 
 Drug patch testing has been found to elicit positive response in 
about 50% of cases with FDE, when there is a high drug imputability158. 
In  populations with low imputability for the tested drug, patch tests were 
positive only in 10% of cases159. 
Pathogenesis of local reaction in patch testing :- 
 This test relies on the penetration of the drug from the patch into 
the epidermis where the hapten – either the parent drug or the reactive 
metabolite formed by  the drug metabolising enzymes in the skin, 
conjugate with host proteins. Conjugates are recognised by MHC 
expressing antigen presenting cells which process and present them to 
effector cells of immune system. This triggers peptide specific CD8+T 
cells to get activated and release proinflammatory cytokines and 
chemokines causing a local response160 . 
 Apart from the time course , the reactions are different from the  
patch test in allergic contact dermatitis both in clinical aspects and their 
pathology. For instance, in some studies, isolated symptoms like pruritus, 
eventually associated with faint erythema are occasionally considered as 
a positive reaction162 . 
  
25
 A working party of European Society of Contact Dermatitis has 
proposed the guidelines for performing skin testing in CADR in an 
attempt to standardize these procedures155. 
GUIDELINES : 
General procedures: 
 Patch tests are usually performed with Finn chamber fixed on 
Scanpor tape.  Ideally the test should be performed both on normal skin 
on the back and on the residual pigmented site of FDE. 
 After informed consent, drug skin tests should be performed 6 
weeks to 6 months after complete healing of the skin lesions. The testing 
is not usually recommended after 8 months of healing of lesion, as 
possibility of obtaining negative results is very high. It is preferable not to 
test during pregnancy. Overfilling or under filling can lead to false 
positive or false negative results respectively. 
CONCENTRATION AND VEHICLES : 
Patch testing with commercialised drug : 
 The drug possibly responsible for FDE can be tested with the 
commercialised drug formulation used by the patient. Pills should have 
their  coating removed and then ground to a very fine powder. Using the 
powder,  a 30% concentration of the drug is prepared either with 
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petrolatum, DMSO, distilled water or 95% alcohol as vehicle. Each 
preparation is made for only  one patient and can be kept for only one 
day. Whenever possible the drug coating, preservatives, colouring agents 
and excipients should also be tested undiluted or diluted at 10% in 
petrolatum. The gel jacket portion of capsule should be moistened and 
tested as is. The highest non irritating concentration is preferred to 
minimise false negative results155. 
Patch testing with pure substance:- 
 Whenever possible, the pure drug obtained from the manufacturer 
should be tested, diluted at 10% in petrolatum and if possible also at 10% 
in aqua or alcohol Recently, standardised material with pure molecules, 
diluted in petrolatum has been commercialised for drug patch tests for 
some drugs(by Chemotechnique laboratory, Sweden)163.  
Drug or Drug Class Concentrations Used and Controls (when available) 
Relapse of the 
CADR Caused by 
Drug Patch Tests 
Acetylsalicylic acid C*:10% in petrolatum — 
Acyclovir Commercialized form - as is, 20%, 
10% and 1% in pet159  
10% in pet164 
Cכ: 10% in pet 
— 
Betalactam antibiotics154.159 10% in pet 
Immediate reactions 
in case of 
anaphylaxis 
Amoxicillin165 Cכ: 10% in pet 
PenicillinG, potassium  
salt  
Cכ: 10% in pet 
Cefotaxime 10% in pet 
Cephalexin 10% in pet 
Dicloxacillin sodium154,166 10% in pet 
Captopril154,167 1% and 10% in pet167 — 
Carbamazepine155,168,169 10% in pet 
Cכ: 1% in pet 
[155] 
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Drug or Drug Class Concentrations Used and Controls (when available) 
Relapse of the 
CADR Caused by 
Drug Patch Tests 
Celecoxib Frequent false 
positive reaction170 
tested at 10% or 1%in pet — 
Chloroquine No true positive 
reaction 
False positive reactions 
The threshold of specificity 
undetermined171 
— 
Chlorpheneramine172 20% in pet (commercialized form) — 
Clindamycin Cכ: 10% in pet — 
Ciprofloxacin173 10% 1n pet — 
Clarithromycin Cכ: 10% in pet — 
Codeine174 1% and 5% in pet — 
Colchicine171 
False positive results 
10% in pet,( 80% of  negative 
controls -  false-positive results)171 
— 
Corticosteroids154,175 If negative, to be diluted in 
ethylalcohol154 
— 
Cotrimoxazole176  10%, 20% or 50% in DMSO, 
frequently negative when diluted 
in pet155  
Cכ: 10% in pet 
 
— 
Cyclines177  
Doxycycline 
Minocycline 
0.1% and 1% in a DRESS 
Cכ: 10% in pet 
10% in pet 
— 
Desloratadine178 Diluted at 10% in pet in 8/10 
volunteers, specific when tested 
diluted at 1% in pet178 
— 
Diclofenac179 1% in pet 
Cכ: 1% in pet 
At 1% pet in an 
anaphylactic 
shock158 
Erythromycin Cכ: 10% in pet — 
Fluoroquinolones 154,59 
 
Norfloxacin 
Ciprofloxacin 
30% in pet or water 
(commercialized form) 
Cכ: 10% in pet 
10% in pet 
— 
Hydantoin Cכ: 10% in pet  
Hydroxyzine154 10% in pet 
Cכ: 1% in pet 
154 
Ibuprofen Cכ: 10% in pet — 
Ketoprofen Cכ: 1% in pet — 
Terbinafine154 As is154 — 
Metamizole180 1% ,10% in petrolatum  
Metronidazole154  — 
Nimesulide79 10% in pet (commercialized form) — 
Omeprazole171 
No true positive reaction 
30% in pet or water 
(commercialized form) 
— 
Oxicams130 1% in pet or 10% in pet  
C∗: piroxicam 1% in pet 
— 
Paracetamol  C∗: 10% in pet _ 
Pseudoephedrine, 181 Tested at 1% in pet to avoid any 
relapse of the CADR 
 
Pet – Petrolatum                 C* - Chemotechnique lab 
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Advice to patient:- 
 Patient should be adviced to keep the patch dry, avoid vigorous 
activities and sunlight exposure. 
Reading:- 
 Patch test reactions need to be read at 20 min, day 2 and day 4 (if 
not possible on day3). Whenever possible if the patch tests are negative 
on day 4, a reading a should be performed on day 7. As drug patch tests 
can elicit immediate positive reactions especially with β-lactam drugs, a 
reading at 20 minutes is made. Results of patch testing should be reported 
according to the International Contact Dermatitis Research group 
(ICDRG) criteria182. 
ICDRG CRITERIA : 
Clinical picture Score Conclusion 
Faint erythema only  ? or +ve  
Erythema, infiltration possibly 
discrete papules  
+  
Erthema, infiltration, papules, 
vesicles 
++  
Intense erythema, infiltration, 
coalescing vesicles  
+++  
 - ve Negative 
 IR Irritant Reaction 
 NT Not Tested 
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 As already mentioned, isolated symptoms like pruritus, eventually  
associated with faint erythema can be considered as a positive reaction.       
With patch tests , cross reactions have been demonstrated. The reactivity 
pattern differs from one patient to another and no general rule of cross 
reactivity can be given163. 
Drug free intervals demanded for drugs decreasing reactivity of 
patch tests  :  
           It is preferable to discontinue systemic steroids or 
immunosuppressive therapy at least 1 month before patch testing183 . 
DRUG FREE INTERVALS : 
Medication Routes Drug free  interval
 H1 antihistamines        Oral, IV             5 days 
 B – adrenergic drugs        Oral, IV            5 days 
 Glucocorticosteroids 
 Long term 
 Short term,high dose 
 Short term,<50mg 
 prednisolone 
 
       Oral, IV 
       Oral, IV 
       Oral, IV 
 
          3 wks 
          1 wk 
          3 days 
Topical steroids  2 wks 
 
FALSE positive results :  
9 Allergy to vehicle itself – very rare with petrolatum 
9 Allergy to some other component of commercialised drug  
9 Over filling of Finn chamber  
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FALSE  negative results : 
9 Inadequate concentration of the drug 
9 Drug not uniformly dispersed in vehicle - poor absorption 
9 Metabolite rather than the drug is the sensitising antigen 
9 Coadministration of immunosuppressive drugs 
9 Exposure to sunlight 
9 Underfilling of Finn chamber 
Other Pit falls : 
 Drug patch tests can reactivate FDE in few cases 
 Patch tests have high positive predictive value and  low negative  
predictive value163. 
SKIN PRICK TEST  (SPT) 
 They are of unknown significance in diagnosing fixed drug 
eruption. They are done on the volar aspect of the forearm with the 
commercialised form of the drug .Whenever possible both the pure drug 
and excipients should be tested. The concentration is the same  as that for 
patch test. A SPT is done by pricking the skin percutaneously with a prick 
needle through the drug solution. Reaction are considered positive when a 
wheal with a diameter >3mm than that of negative control appear.If 
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control is positive, a wheal of diameter 3 mm more than control is 
considered positive. Reading is usually taken at 20 min and one day 
later155. 
INTRADERMAL SKIN TESTS: 
 When SPT gives a negative result, intradermal test can be done. 
Guidelines : 
 Dilutions are prepared under laminar flow no longer than 2 hrs 
preceeding administration. 
 Intense monitoring of patients is a must as IDT can precipitate 
CADRs. 
 Sterile solutions of the suspected drug diluted sequentially (10-4, 
10-3, 10-2, 10-1) in phenolated saline or in 0.9% saline is used. 
 The tests are performed on the extensor surface of the arm , with a 
0.04ml that produces a wheal of 4-6 mm in diameter. 
 Tests are initially read after 30 minutes with each serial dilution. A 
wheal of > 10 mm diameter is considered positive. 
 Intradermal test result readings are taken at 30 min, 6 hrs & 1 day . 
 When the results are negative, a delayed reading at 1 wk should be  
taken. 
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 Among these skin tests available drug patch testing is found to be 
more useful. The significance of SPT & IDT in FDE is unknown155. 
DRUG PROVOCATION TEST :  
 Provocation tests are regarded as gold standard to establish or 
exclude the presence of hypersentivity  to a drug. Provocation testing is 
potentially harmful and should be considered only after balancing the risk 
benefit ratio in a patient. 
 It is defined as a controlled administration of a drug under medical 
surveillance to diagnose drug hypersensitivity 
Procedure : 
 General guidelines for DPT have been proposed by the European 
network for Drug Allergy and the European Academy of Allergology and  
Clinical Immunology interest group on hypersensitivity : 
 DPTs should be performed  4 wks after drug hypersensitivity or       
after at least five drug elimination cycles have passed since the 
ADR episode. 
 The drug should be administered by the same route and in the same 
form that it was originally taken. 
 Escalating doses should be used. 
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 Comedication that could affect the drug pharmacokinetic profile 
should be eliminated. 
 The patient should be in good health with no comorbidity risks. 
 Rechallenge should take place in a controlled environment with  
resuscitation facilities. 
 Good documentation following controlled protocols and  
assessment systems should be used to document responses. 
 Contraindications include pregnancy, significant comorbidity,  
increased risk caused by life-threatening reactions such as the 
bullousreactions, erythroderma, DHS, anaphylaxis, systemic    
vasculitis, and drug induced autoimmune disease. 
 No alternate tests are available to aid diagnosis. 
 As a rule commercialised preparations are used and Compounds 
should be tested separately in sequence in case of multiple drug intake. 
The time interval between doses should be atleast 30 minutes. Depending 
on the drug and patient's response threshold, a DPT may be concluded 
with in a few hrs, days or occasionally weeks. 
 DPT may also be performed to find an alternative drug in which 
case, the maximum single therapeutic dose should be achieved. 
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Test Results : 
 A DPT may be considered + ve if it reproduces the original 
symptoms or  atleast objective ones156 
MANAGEMENT : 
- Withdrawal and avoidance of the offending drug  : 
 The physician should advise the patient regarding  
 a. Drug(s) that may have caused the eruption and those to be 
avoided. 
 b. Drug(s) that can be used 
- Symptomatic treatment with antihistamines ,emollients 
- Oral and topical steroids 
- Topical triple drug combination – topical steroids, retinoids and 
hydroquinone for residual hyper pigmentation 
- There are reports of successful desensitisation to allopurinol in 
patients with FDE to allopurinol190.   
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AIM 
¾ To find out the incidence, age and sex distribution of Fixed Drug 
Eruption among patients attending the Department of 
Dermatology, Government General Hospital, Chennai. 
¾ To find out the proportion of FDE cases  among various cutaneous 
adverse drug reactions.        
¾ To find out the common offending drugs and study the drug 
specific clinical patterns and sites of involvement in the FDE cases. 
¾ To study the different parameters of fixed drug reaction -   Number 
of episodes in a patient and mean length of time from drug 
exposure to the development of FDE lesions during initial and 
subsequent episodes. 
¾ To confirm the drugs responsible for causation  through patch 
testing.   
¾ To study the various histopathological characteristics of fixed drug 
eruptions.  
¾ To ascertain the role of CD8+ T-cells in causation through 
Immunohistochemistry. 
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MATERIALS AND METHODS 
STUDY PERIOD AND DESIGN :   
 A cross sectional study where in 76 patients who presented with 
Fixed drug eruption to the Department of Dermatology, Government 
General Hospital, Chennai from Aug 2008- Aug 2010 were analysed. 
 Patients with Fixed drug eruptions attending or referred to our 
department  with definite history of drug intake prior to the onset of 
lesion were included in the study. The approval of the ethical committee 
was obtained before commencing the study. 
CLINICAL PROFILE :       
 The history and clinical examination of selected subjects were 
recorded on a predesigned proforma. Preliminary informations like age, 
sex, occupation and addresses were noted down. 
A detailed inquiry was made on the following aspects 
• Nature of the drug ( Allopathy /Others) 
• Drug Details : 
 - Name of the drug/ drugs 
 - Single or multiple 
 - Complaints for which they were prescribed 
  
37
• Duration of lesions 
• Number of episodes of FDE 
• Time interval between drug exposure and occurrence of lesions 
• Site of occurrence and Nature of lesions 
• Increase in number and size of FDE lesions during subsequent 
episodes in recurrent cases 
• Associated local and systemic symptoms 
• Others - History of atopy 
   - Family history of drug allergy 
   - Sexual history 
 Each patient was subjected to a thorough general and systemic 
examination. Dermatological examination included the morphological 
pattern of drug eruption, site of lesions and number of lesions. 
 Haematological investigations included Complete blood count and 
absolute eosinophil count. Blood VDRL and HIV ELISA testing were 
done in all patients. 
 The causality of the suspected drug was established by using  
‘WHO-MHC causality assessment criteria’. Patch testing was done in all 
willing patients in an effort to identify the causative drug. The test was 
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done according to the guidelines proposed by the European society of 
contact dermatitis. 
 Drug patch testing was done 6 weeks after complete healing of 
lesions. The test was deferred in pregnant women and in patients with 
FDE lesions of more than 8 months duration. Prior to testing, patients 
were asked to abstain from potentially offending drugs, antihistamines, 
steroids and immunosuppressives. Topical corticosteroids were 
discontinued atleast 2 weeks prior to the test. Patients were asked to avoid 
sun exposure and vigorous activities. 
 The test was done on both the lesional skin and the unaffected skin 
on the back. In cases with mucosal FDE, patch testing was done on 
normal skin of the back. In patients with unknown drug history, patch 
testing was done with the common offending agents, based on the 
complaint for which the drug was prescribed. 
 A standard concentration of the incriminated drug was prepared by 
dispersing the commercialised drug form in petrolatum and applied using 
a Finn chamber on Scanpor tape. The readings were taken on day 2 and 
day 4, and graded based on ICDRG criteria182. As followed in few 
previous studies, isolated local symptoms like itching and burning 
sensation were also considered to be positive162. 
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 Biopsy was done in 33 patients after informed consent and the 
specimen was subjected to histopathological examination, after staining 
with Hematoxylin and Eosin. 
 Immunohistochemical analysis using antibodies to CD8 was done 
in 8 patients (4 with acute lesions and 4 with residual hyperpigmented  
patch). Intradermal and oral provocation tests were deferred, as it was not 
possible to get the approval of the ethical committee of our institution. 
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OBSERVATIONS 
INCIDENCE : 
 The incidence of fixed drug eruptions among OPD patients was 
found to be 0.54%.  FDE was the second common cutaneous adverse 
drug reaction pattern constituting 24.83% cases (76 out of 306). 
Maculopapular rash was the most common cutaneous adverse drug 
reaction pattern constituting 29.25% of cases.  
AGE AND SEX DISTRIBUTION 
 The maximum number of cases were in the age group of 21-30 yrs 
constituting 46.1 %(n = 36). The youngest patient was 8 months old and 
the oldest patient was 75 years old. The male to female ratio was 1.23:1 
(42:34). The mean age of male patients was 30.69 years (S.D ± 14.75) 
and that of females was 31.91 years (S.D ± 13.35).  
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AGE&SEX DISTRIBUTION (Fig. 1) 
Age group 
SEX 
Total 
Male Female 
≤ 10 yrs 
No.of cases 2 1 3 
% within age group  66.7% 33.3% 100.0% 
% of Total 2.6% 1.3% 3.9% 
11-20 yrs 
No.of cases 3 3 6 
% within age group  50.0% 50.0% 100.0% 
% of Total 3.9% 3.9% 7.9% 
21-30 yrs 
No.of cases 20 15 35 
% within age group  57.1% 42.9% 100.0% 
% of Total 26.3% 19.7% 46.1% 
31-40 yrs 
No.of cases 8 7 15 
% within age group  53.3% 46.7% 100.0% 
% of Total 10.5% 9.2% 19.7% 
41-50 yrs 
No.of cases 4 4 8 
% within age group  50.0% 50.0% 100.0% 
% of Total 5.3% 5.3% 10.5% 
51-60 yrs 
No.of cases 3 3 6 
% within age group  50.0% 50.0% 100.0% 
% of Total 3.9% 3.9% 7.9% 
> 60 Yrs 
No.of cases 2 1 3 
% within age group  66.7% 33.3% 100.0% 
% of Total 2.6% 1.3% 3.9% 
Total 
No.of cases 42 34 76 
% within age group  55.3% 44.7% 100.0% 
% of Total 55.3% 44.7% 100.0% 
P value  - 0.667 (insignificant difference in sex incidence) 
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DURATION OF LESION: 
DURATION OF FDE NO : OF PATIENTS 
< 1 WEEK 8 (10.52%) 
1 - 4  WEEKS 4 (5.26%) 
1 - 6 MONTHS 5(6.58%) 
6 - 12 MONTHS 4(5.26%) 
1 - 2 YEARS 38(50%) 
2 - 4 YEARS 17(22.36%) 
 
            The duration of lesions varied between 2 days and 4 years. On an 
average the time period of an acute episode was 4.2 weeks. In patients 
with recurrent episodes, the disease was present for a duration of less than 
a year in 11.29 % of cases, for 1-2 years in 61.29% cases and for 2-4 
years in 27.42%.  
NUMBER OF EPISODES (Fig.2):  
NO : OF EPISODES NO : OF CASES PERCENTAGE
1 14 18.4 
2-5 51 67.1 
5-10 11 14.5 
TOTAL 76 100 
 
 14 patients (18.4%) had developed FDE for the first time.51 
patients (67.1%) had 2-5 episodes and  11(14.5%) had suffered  6-10 
episodes. 
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MEAN TIME INTERVAL :           
EPISODE OF FDE MEAN TIME INTERVAL 
FIRST EPISODE 13.4 DAYS 
SUBSEQUENT EPISODES 4.65 hrs 
              
 A statistically significant difference was observed with regards to 
the incubation period in the initial and subsequent episodes. The mean 
time interval between drug intake and occurrence of FDE was found to be 
13.4 days (S.D ± 4.75 days) in the first episode. The minimum time 
interval noted was 7 days and the maximum time interval was 22 days. 
The mean time of onset of lesions in subsequent episodes was 4.65 hrs 
(S.D ± 2.89 hrs). The minimum time interval noted was 20 minutes and 
the maximum time interval was 36 hrs. 
MORPHOLOGICAL PATTERN OF PRESENTATION:   
MORPHOLOGICAL  
PATTERN NO : OF CASES PERCENT 
CLASSICAL 62 81.57% 
BULLOUS 14 18.42% 
NONPIGMENTING 
(Bullous) 1 1.33% 
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 The FDE lesions were mainly of the classical type in 65.8%  
(n = 62)  of cases, with initial erythematous, edematous patches healing 
with residual hyperpigmentation. Bullous FDE was the presenting feature 
in 18.42% (n = 14). There was one (1.33%) interesting case of 
nonpigmenting FDE involving the palms.  
DISTRIBUTION OF LESIONS: 
PATTERN OF 
DISTRIBUTION 
NO : OF CASES WITH 
PERCENTAGE 
LOCALISED SOLITARY 12(15.79%) 
LOCALISED MULIPLE 5(6.57%) 
MULTIFOCAL 41(53.95%) 
GENERALISED 4(5.26%) 
TOTAL 76 
 
          The lesions were multifocal in 53.95% cases (n = 41), solitary in 
15.79%cases (n = 12) and generalised in 5.3% cases (n = 4) .For the 
patients with solitary lesions, it was their first episode of FDE. 
NUMBER OF LESIONS: 
NO : OF LESIONS NO : OF PATIENTS 
1 12(15.79%) 
2 – 5 28(36.84%) 
6 – 10 23(30.26%) 
11 – 30 9(11.84%) 
> 30 4(5.3%) 
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 12 patients (15.79%)  had single lesion, 28 patients (36.84%) had 
2-5 lesions, 23 patients (30.26%) had 6-10 lesions, 9 patients (11.84%) 
had 10-30 lesions and 4 patients (5.3%) had generalised involvement  
with more than 30 lesions. 55(85.94%)  out of 62 patients with recurrent 
episodes showed increase in size and numbers of lesions during 
subsequent episodes. 
SHAPE AND SIZE OF LESION: 
 The lesion were mostly circular seen in 84.21%patients (n = 64). 
11.84% patients (n = 9) had presented with irregular hyperpigmented 
patches and 3.9% (n = 3), with large polycyclic lesions. The size of the 
lesions varied from 0.5 cm to 15 cms. 
DRUGS INCRIMINATED IN CAUSATION (Fig.3): 
 There was a definite history of drug intake in all patients. All of 
them had developed FDE after intake of allopathy drugs. None of them 
gave history of intake of indigenous medicine prior to the onset of 
lesions. There was no family history of drug allergy in any of them. There 
was no personal or family history of atopy in any of them. 
 The exact drug details were known only in 63 patients (82.9%).            
49 out of them (77.78%) gave history of single drug intake in the form of 
over the counter medications and 14 (22.22%) had history of intake of 
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multiple drugs. In the remaining 13 patients (17.11%), the drug details 
were not known. 
 The identification of the offending drug was confirmed by patch 
testing in 25 out of 64 willing patients (32.9%). It was negative in the 
remaining 39 patients. 6 patients (7.9%) were not willing for patch testing 
and 4 patients (7.9%) failed to report for follow up. Among the 39 
patients with negative patchtest results, 7(17.94%) had mucosal FDE and 
6 (15.38%) presented with unknown drug details.  
NAME OF DRUG FREQUENCY PERCENT 
CIPROFLOXACIN 11 14.5 
COTRIMOXAZOLE 9 11.8 
LEVOFLOXACIN 8 10.5 
DICLOFENAC 7 9.2 
PARACETAMOL 6 7.9 
PHENYTOIN 5 6.6 
DOXYCYCLINE 4 5.3 
METRONIDAZOLE 4 5.3 
NORFLOXACIN 2 2.6 
BRUFEN 2 2.6 
CARBAMAZEPINE 2 2.6 
CHLOROQUINE 1 1.3 
FLUCONAZOLE 1 1.3 
NIMESULIDE 1 1.3 
DETAILS UNKNOWN 13 17.1 
TOTAL 76 100 
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 Fluoroquinolones were the most common offending group of 
drugs. Ciprofloxacin topped the list, responsible in 11 cases (14.5%) 
followed by levofloxacin in 8 cases (10.5%). Cotrimoxazole induced 
FDE in 9 cases (11.8%), out of which 4 were children less than 14 years 
of age. The other antibacterials included doxycycline, metronidazole 
which accounted for 4 cases each (95.3%) and norfloxacin which was the 
offender in 2 cases (2.6%). 
 Nonsteroidal anti-inflammatory drugs were the second commonly 
incriminated group of drugs with diclofenac being the causative drug in 7 
cases (9.2%), followed by paracetamol in 6 cases (7.9%). 
 Among the anticonvulsants, the main inducer was phenytoin 
involved in 5 cases (6.6%).  
SITE OF INVOLVEMENT: 
 The most frequently involved site was extremities (n = 34; 
44.73%), followed by the trunk (n = 26; 34.2%), face (n = 17; 22.4%) and 
mucosa  (n = 14; 18.42 %). Others less frequent sites included palms and 
soles (n = 6, 7.9%), lips and perioral areas (n = 7, 9.2%). 
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SEX SPECIFIC SITE OF INVOLVEMENT (Fig.4): 
SITE OF FDE MALE FEMALE 
P - Value 
(Chi square) 
EXTREMITIES 15(44.1%) 18(55.9%) 0.079 
TRUNK 13(50%) 13(50%) 0.506 
FACE 7(41.2%) 10(58.8%) 0.185 
ORAL MUCOSA 6(75%) 2(25%) 0.092 
GENITALIA 6(85.71%) 1(14.28%) 0.089 
LIPS AND PERIORAL 2(28.6%) 5(71.4%) 0.136 
PALMS AND SOLES 5(83.3%) 1(16.7%) 0.150 
 
 The collected data was statistically analysed using SPSS, version 
15 for windows. There was also no statistically significant difference in 
the involvement of face, lips, trunk, extremities, mucosa and palms and 
soles between males and females. However, clinically oral and genital 
involvement were most frequently documented in males, with oral 
involvement seen in 75% (n = 6) of males and genital involvement in 
85.71% (n = 6) of males. Lip and perioral involvement was more 
frequently encountered in females (71.4%). Males predominantly showed 
involvement of palms and soles (83.3%) when compared to females 
(16.7%).  
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DRUG SPECIFIC SITE OF INVOLVEMENT (Fig.5):  
NAME OF THE DRUG 
EXTREMITIES 
(n = 41) 
TRUNK 
(n = 26) 
FACE 
(n = 17) 
ORAL 
MUCOSA 
(n = 8) 
GENITALIA 
(n = 7) 
LIPS & 
PERIORAL 
(n = 7) 
PALMS & 
SOLES 
(n = 6) 
OTHERS 
CIPROFLOXACIN (11) 7 (63.63%) 4 (36.36%) 2 (18.18%) 1 (9.09%) 1(9.09%) 1(9.09%) - - 
COTRIMOXAZOLE (9) 2 (22.22%) 3 (33.33%) 2 (22.22%) 2 (22.22%) 2 (22.22%) 2 (22.22%) - 
PERI 
OCULAR 
LEVOFLOXACIN (8) 5 (62.5%) 2 (25%) 5(62.5%) 1 (12.5%) 1 (12.5%) - - - 
DICLOFENAC (7) 1 (14.28%) 4 (57.14%) 2 (28.57%) 2 (28.57%) - 2 (28..57%) 1 (14.28%) - 
PARACETAMOL (6) 4 (66.67%) - - - - - 4 (66.67%) - 
PHENYTOIN (5) - 5(100%) - - - - - - 
DOXYCYCLINE (4) 1 (25%) - 1 (25%) 1 (25%) 1 (25%) - - - 
METRONIDAZOLE (4) - 3 (75%) 2 (50%) 1 (25%) - - 1 (25%) - 
NORFLOXACIN (2) - - 2 (50%) - - 1 (50%) - - 
BRUFEN (2) 2 (100%) - - - - - - - 
CARBAMAZEPINE (2) 1 (50%) 1 (50%) - - - - - - 
FLUCONAZOLE (1) 1 (100%) - - - - - - - 
NIMESULIDE (1) - 1 (100%) - - - - - - 
CHLOROQUINE (1) 1 (100%) - - - - - - - 
DETAILS 
UNKNOWN(13) 9 (69.23%) 4 (30.77%) 1 (7.69%) - 1 (7.69%) 1 (7.69%) - - 
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            The data concerning the FDE sites and FDE inducer drugs was 
statistically analysed using SPSS, version 15 for windows to identify the 
relation of FDE sites to the drugs incriminated in causation. Statistical 
evaluation was done using chi- square tests and p values lower than 0.05 
were considered significant.  The results of the analysis showed no 
statistical association was found between FDE sites and FDE inducer 
drugs. 
NAME OF THE 
DRUG SITE P – VALUE 
CIPROFLOXACIN EXTREMITIES 0.818 
LEVOFLOXACIN FACE 0.5 
PARACETAMOL PALMS & SOLES 0.667 
PHENYTOIN TRUNK (100%) COMPARISON IMPOSSIBLE 
  
 Though statistically insignificant, certain clinically significant 
associations found in our study are as follows : 
i. Ciprofloxacin more frequently induced lesion on extremities 
(n = 7, 63.63%).  
ii.  Levofloxacin mainly produced lesion on trunk and face  
(n = 5, 62.5%). 
iii. Cotrimoxazole induced FDE lesions in all sites with almost 
equal frequencies. 
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iv. Paracetamol was found to preferentially involve the palms 
and soles (n = 4, 66.67%). 
v. Phenytoin induced lesions only on the trunk (n = 5,100 %). 
vi. Mucosal FDE: 
  Oral mucosa [n = 7;9.2%] : 
 The main drugs incriminated were cotrimoxazole and diclofenac 
each constituting 2 cases (28.57%). Other offending drugs included 
metronidazole, doxycycline, levofloxacin and ciprofloxacin, each 
constituting one case (14.28%). Isolated oral involvement was seen in 5 
cases(71.42%). In the mouth, labial mucosa (n = 6, 75%) and hard palate 
(n = 2, 25%) were involved. 
  Genital mucosa [n = 7 ;9.2%] : 
          The main inducers were cotrimoxazole (n = 2, 28.57%) followed 
by ciprofloxacin, levofloxacin, doxycycline and brufen, in 1 case 
(14.28%) each. Isolated genital involvement was seen in 4 cases 
(66.67%). Glans penis was involved in 4 patients (57.14%), scrotum in 
two patients (28.57%) and vulva in one patient (14.28%). 
Others :  
- Lips and Perioral area : The frequent inducers were cotrimoxazole 
and diclofenac contributing to two cases (28.57%) each.  
- Periocular involvement was seen in 1 patient (1.31%) due to 
cotrimoxazole. 
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DRUG SPECIFIC PATTERN OF INVOLVEMENT (Fig.6): 
DRUGS 
CLASSICAL (n = 62) BULLOUS (n = 14) 
NONPIGMENTING 
(n = 1) 
LOCALISED (n = 17) MUILTIFOCAL
(n = 41) 
GENERALISED
(n = 4) 
MUILTIFOCAL
(n = 13) 
SOLITARY 
(n = 1) SOLITARY(12) MULTIPLE(5)
CIPROFLOXACIN 2 - 4 2 3   
COTRIMOXAZOLE 4 1 1 1 2   
LEVOFLOXACIN - - 7 - 1   
DICLOFENAC 2 1 2 - 2   
PARACETAMOL - - 2 - 3 1 1 
PHENYTOIN - - 5 - -   
DOXYCYCLINE 3 - 1 - -   
METRONIDAZOLE - 1 2 1 -   
NORFLOXACIN - 2 - - -   
BRUFEN - - 2 - -   
CARBAMAZEPINE - - 1 - 1   
FLUCONAZOLE - - 1 - -   
NIMESULIDE - - 1 - -   
CHLOROQUINE - - 1 - -   
DETAILS 
UNKNOWN 1 - 11 - 1   
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1) CLASSICAL FDE (n = 62, 81.57%) : 
• LOCALISED CLASSICAL (n = 17, 22.36%): 
- SOLITARY LOCALISED (n = 12, 15.79%) :  
 Cotrimoxazole induced solitary classical FDE lesions in 4 patients 
(33.33%), followed by doxycycline in 3 patients(25%), diclofenac and 
ciprofloxacin in 2 patients each(16.67%). The drug detail was unknown 
in 1 patient. 
- MULTIPLE LOCALISED (n = 5,6.57%) :  
 Norfloxacin produced localised multiple FDE lesions on the face in 
patients (40%).Cotrimoxazole, metronidazole and diclofenac were 
responsible in 1 case each (20%). 
• MULTIFOCAL CLASSICAL (n =  41, 53.95%) : 
 Most of the multifocal classical FDE lesions were induced by 
levofloxacin (n = 7,17.07%).The other drugs in the decreasing order of 
frequency were phenytoin (n = 5, 12.19%), ciprofloxacin (n = 4, 9.75%), 
paracetamol (n = 3, 7.31%), brufen (n = 2, 4.88%), diclofenac (n = 2, 
4.88%), metronidazole (n = 2, 4.88%), carbamazepine (n = 1. 2.44%), 
chloroquine (n = 1, 2.44%), fluconazole  (n = 1, 2.44%) and nimesulide 
(n = 1, 2.44%). 2 patients with multifocal FDE lesions (more than 15 
lesions) were found to be HIV ELISA positive.  
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• GENERALISED CLASSICAL FDE (n = 4, 5.26%) : 
 Generalised classical FDE lesions were encountered with 
ciprofloxacin in 2 cases (50%), cotrimoxazole and carbamazepine in one 
case each (25%).  
2) BULLOUS FDE (n = 14, 18.42%) : 
 Most of the cases of bullous FDE had multifocal lesions (n = 13, 
92.86%) and were attributed to paracetamol (n = 4, 23.08 %) mainly, 
followed by ciprofloxacin (n = 3, 15.38%), cotrimoxazole (n = 2, 
15.38%),  diclofenac (n = 2, 15.38%), and carbamazepine (n = 1, 7.14%). 
The drug details were unknown in one patient (7.14%). 
 We had one case of solitary bullous FDE on the palms induced by 
paracetamol. In total, paracetamol was the offender in 4 cases of bullous 
FDE on the palms and soles (including one case of nonpigmenting 
bullous FDE). 
3) NONPIGMENTING FDE(n = 1, 1.3%) :       
 There was one case of nonpigmenting bullous FDE on the palms 
and soles caused by paracetamol.                 
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ASSOCIATED SYMPTOMS : 
ASSOCIATED SYMPTOMS NO : OF PATIENTS 
LOCAL : n = 60  (78.95%) 
ITCHING 48(80%) 
BURNING 12(20%) 
ASYMPTOMATIC 16(21.05%) 
GENERAL : n = 11  (14.47%) 
GENERALISED ITCHING 6(7.89%) 
FEVER WITH MYALGIA 3(3.94%) 
HEADACHE 2(2.63%) 
ABDOMINAL PAIN 2(2.63%) 
 
LOCAL SYMPTOMS : 
 60 (78.95%) patients had associated local symptoms. 48 of them 
had itching (80%) and 12(20%) had local burning pain. The lesions were 
asymptomatic in the rest (21.05%). 
GENERAL SYMPTOMS : 
 11(14.47%) patients had associated constitutional symptoms. 
Generalised itching was encountered in 6 patients (7.89%). Associated 
constitutional symptoms were seen in 7 patients (9.21%) during the acute 
spisodes. 3(3.94%) of them had fever with myalgia, 2 (2.63%) had 
headache and 2 (2.63%) had abdominal pain with nausea. In all the 7 
patients, constitutional symptoms developed only after drug intake and 
the drugs responsible were prescribed for unrelated complaints. 
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ROUTINE INVESTIGATIONS : 
 69 out of 76(90.79%) cases had associated eosinophilia., HIV 
ELISA was positive in two patients with multifocal classical FDE (2.6%). 
DRUG PATCH TEST RESULTS (Fig. 7): 
 25 out of 64 (32.9%) patients showed positive patch test results. 
Among these 25 cases, 22 had skin involvement and 3 had mucosal 
involvement. In all the 22 cases, drug patch testing done on the lesional 
skin was positive. Except for the 3 cases with mucosal FDE (12%), drug 
patch testing done on the unaffected skin was found to be negative.  
NAME OF THE DRUG 
TOTAL 
NO: OF 
CASES 
PATCH 
TEST 
POSITIVE 
PATCH 
TEST 
NEGATIVE 
UNWILLING / 
LOST 
FOLLOW 
CIPROFLOXACIN(11) 11 4 (36.36%) 7 - 
COTRIMOXAZOLE(9) 9 5 (62.5%) 3 1 
LEVOFLOXACIN(8) 8 3 (37.5%) 5 - 
DICLOFENAC(7) 7 2 (28.5%) 5 - 
PARACETAMOL(6) 6 2 (33.33%) 4 - 
PHENYTOIN(5) 5 2 (100%) - 3 
DOXYCYCLINE(4) 4 2 (66.67%) 1 1 
METRONIDAZOLE(4) 4 1 (25%) 3 - 
NORFLOXACIN(2) 2 - 1 1 
BRUFEN(2) 2 1 (50%) - 1 
CARBAMAZEPINE(2) 2 1 1 - 
CHLOROQUINE(1) 1 1 - - 
FLUCONAZOLE(1) 1 1 - - 
NIMESULIDE(1) 1 1 - - 
DETAILSUNKNOWN(13) 13 - 8 5 
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• The patch test positivity rate was the highest with doxycycline 
(66.67%). 
• When patch testing was done with cotrimoxazole, Dimethyl 
sulfoxide was used as vehicle to enhance the positivity of results. 
The rate of positivity observed was 62.5%.  
• With fluoroquinolone group of drugs, the rate of positivity was 
relatively low. When tested with ciprofloxacin, levofloxacin and 
norfloxacin, the positivity rates were 36.36%, 37.5% and 0% 
respectively. 
• Patch testing with paracetamol was positive in 33.33% of cases. 
• Testing with diclofenac and metronidazole also revealed low rates 
of positivity (28.5% and 25% respectively). 
• Only 4 out of 7 patients in whom anticonvulsants were the main 
offenders agreed for patch testing. 3(75%) of them showed positive 
test results. 
• 4 (16%) patients had developed delayed positive reactions with 
negative patch test reading on day 2 and positive test results on  
day 4. 
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• Only 8 out of 13 patients who presented with unknown drug 
history were willing for patch testing. The test result was negative 
in all of them.  
BIOPSY RESULTS  
 Biopsy was performed in 43.45% (n = 33) of patients ; 44.7% of 
patients refused biopsy and 11.8% of patients had lost follow up. Out of 
the 33 willing patients, 15 (45.45%) had acute lesions. The remaining 18 
(54.55%) had residual hyperpigmented patch. The histopathological 
findings were consistent with FDE in all of them. 
 In patients with acute classical lesions the following findings were 
recorded :  
 Epidermal spongiosis was seen in 10 patients (66.67%). Basal cell 
degeneration with necrotic keratinocytes and few dermal melanophages 
was seen in all of them. The papillary dermis showed dense band of 
inflammatory infiltrates in close approximation to the basal layer in 12 
patients (80%).The infiltrates were less dense in the rest (20%). 
Perivascular inflammatory infiltrates were seen in all of them. Few cases 
showed an admixture of eosinophils and neutrophils in the dermis. In 
patients with bullous FDE, a sub epidermal bulla was seen in addition. 
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 In long standing cases (n=18) with residual hyperpigmentation, the 
infiltrates were relatively less dense when compared to acute lesions. The 
density of melanophages was variable. When compared to acute lesions, 
the density of melanophages was found to be greater in chronic lesions. 
There was an intense density of melanophages in the upper dermis in two 
patients (11.11%).    
IMMUNOHISTOCHEMICAL ANALYSIS 
 Immunohistochemical analysis using anti CD8 antibodies was done 
in 8 cases (4 with acute FDE lesion and 4 with residual 
hyperpigmentation). The presence of CD8+ T-cells was demonstrated in 
all of them. The specimen from acute cases showed dense focal collection 
of CD8+ T-cells at the sites of FDE lesions. In all the 4 patients, the  
upper dermis showed collection of CD8+ T-cells. The intraepidermal 
collection was found to be sparse in all the 4 cases. 
Immunohistochemistry of  biopsy specimen from chronic cases showed 
few, sparse CD8+ resting T-cells in the upper dermis. 
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DISCUSSION 
 In our study the incidence of Fixed drug eruption was found to be 
0.54% among Dermatology OPD attendees. The incidence from different 
reports seems to vary from 2.5% to as high as 22%10,11. Factors like 
geographic area, availability of drugs and their usage, age group, literacy 
status, socioeconomic factors, availability of over the counter medications 
etc affect the incidence of FDE10. 
 FDE was the second common cutaneous adverse drug reaction 
pattern (23.47%) encountered. Maculopapular rash was the most common 
CADR pattern observed in 29.25% of cases. However, according to many 
Indian studies, FDE is the most common CADR observed12,13. One study 
from North India17 and studies from western world16,17 have produced 
similar results.    
 Our study reflects a broad patient age range from 8 months to 75 
years. The main age group affected in our study was 21-30 years. This is 
in accordance with the previous studies on FDE, conducted in Pakistan by 
Mahboob and Haroon40 and in Nigeria by Nnoruka72. The opportunity for 
exposure to drugs causing FDE is probably high in this age group. 
However all age groups are vulnerable to FDE. 
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 The male to female ratio in our study was 1.23:1. The slight male 
preponderance did not reveal any statistical significance. The occurrence 
of FDE appeared to be almost equal in both sexes .This is in concordance 
with few previous studies - Mahoob et al reported a sex incidence of 
1.1:140 and Nnoruka et al72 reported a sex incidence of 1.3:1 in their 
respective studies. However, earlier studies showed a male 
preponderance10,11. A recent 3 year analysis of FDE lesions in hospital 
settings in France done by Brahimi N showed controversial results. 
Females were frequently affected with late age at presentation of FDE184. 
 In our study there was no report of occurrence of FDE following 
intake of indigenous medicine. None of our patients had family history of 
drug allergy. There was no personal or family history of atopy in any of 
them. The occurrence of FDE in atopic individuals has been reported by 
Mahboob and Taroon40. 
 14% of patients had FDE for the first time. This is in conformity 
with the previous studies done by Mahboob et al and Nnoruka et al 
(13.3% and 19% respectively)40,72. 13% had suffered more than 5 
episodes of FDE. Most of them had attended our OPD for other 
dermatological problems. The patients with recurrent episodes were not 
bothered of their.  
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 In the current study, the mean time interval between drug exposure 
and occurrence of FDE during the first episode was 13.14 days and that 
during subsequent episodes was 4.65 hours respectively. The difference 
in time interval was found to be statistically significant. During recurrent 
episodes, FDE was found to occur as early as 20 minutes in our study. 
The incubation period observed in our study, during the initial and 
subsequent episodes correlates well with the time period quoted in 
literature4,39. It takes a few weeks for sensitisation to occur to a particular 
drug initially. Once sensitisation occurs, the resting memory CD8+               
T-cells get reactivated on subsequent drug exposures and produce the 
lesions within a few minutes to hours, representing a form of recall 
phenomenon. 
 The common morphological pattern described by all previous 
studies is an erythematous macule evolving into an edematous plaque 
subsiding with residual hyperpigmentation. In the current study, this 
classical presentation was seen in 81.57% of cases. 2 other clinical 
patterns encountered were Bullous FDE(18.42%) and Nonpigmenting 
FDE(1.3%). 
 Multifocal or scattered pattern of distribution was the most 
frequent pattern seen in our patients. The pattern of distribution of lesions 
ranged between solitary and generalised involvement. Extensive and 
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generalised involvement seen in 5.3% of cases necessitates the 
importance of early detection of the responsible drug. Hospital admission 
is necessary for these patients as this form of FDE closely mimics SJS 
and TEN125-127. 
 In our study, the largest size of FDE lesion seen was 15cms. 
Though circular lesions were very common, irregular patches and 
polycyclic lesions were also seen. The occurrence of polycyclic lesions is 
very rare and was first reported by Mahboob and Haroon in Pakistan40. 
These lesions are seen in cases with recurrent episodes, where the 
individual lesions fuse together to produce polycyclic forms.  
 The most common causes of FDE varied according to the various 
geographic areas. The true incidence of FDE for a particular drug 
depends on the frequency of its use 10. In developing countries like ours, 
the problem is further compounded because of the availability of over the 
counter medications and indigenous drug preparations. Despite all these 
factors, the most common drug incriminated according to various study 
reports from India12,185, Turkey, Pakistan40 and Libya186 was 
cotrimoxazole. Antimalarials (pyrimethamine and sulfamethoxazole)  
were the most common inducers in a study done in Nigeria72. According 
to the study conducted by Brahimi N in France184, paracetamol was the 
most common offending drug. Tetracyclines were the main  offenders in 
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a study conducted in Singapore by Chan187. Compared with previous  
reports, the causative drugs varied from decade to decade. In our study, 
fluoroquinolones were the major culprits contributing to 27.63% of cases. 
The main inducers in this group were ciprofloxacin (14.48%) and 
levofloxacin (10.53%). So far no other studies  have cited these group of 
drugs as the most common offenders. The great majority of reports of 
FDE due to fluoroquinolones have been recent. S.Dhar has described 7 
cases with FDE to ciprofloxacin in 1996188. In his study, he has quoted 
that, with widespread use, ciprofloxacin could become one of the 
common drugs causing FDE in future. The findings in our study have 
justified this statement.  
 Cotrimoxazole was the second common inducer next to 
ciprofloxacin, responsible for 11.84% of FDE cases. Nearly half of the 
patients (4/9) were children less than 14 years of age .This is attributed to 
the increased rate of prescription of cotrimoxazole for pediatric patients 
in government hospitals. Owing to the increased occurrence of drug 
allergies to sulphonamides, private medical practitioners are hesitant to 
prescribe this group of drugs nowadays. In our study, the other 
antibacterials that need special mention include norfloxacin,     
metronidazole and doxycyline. 
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 Nonsteroidal anti-inflammatory drugs were the second important 
offending group of drugs with diclofenac topping the list. Diclofenac is 
the most commonly prescribed drug for myalgia and arthralgia in out 
patient departments. However the reports of FDE occurring to diclofenac 
are relatively few. FDE to diclofenac was first reported in 1998 by 
Mahboob and Taroon40. Paracetamol, the most frequently prescribed over 
the counter drug, was responsible in 7.89% of cases. There was one case 
in our study, related to nimesulide intake. So far very few cases of FDE 
occuring to nimesulide have been reported in literature79,189. Among the 
anticonvulsants, the main offender was phenytoin(5.6%). The other less 
common inducer was carbamazepine. There are recent reports of 
increased cross sensitivity and polysensitivity among these group of 
drugs87. This fact should be kept in mind while deciding on alternate 
drugs. 
 Regarding the drug specific pattern of involvement, bullous FDE 
was mainly attributed to ciprofloxacin involving 28.57% of cases. There 
are a few reports of multifocal or generalised bullous eruptions to 
ciprofloxacin available in literature58,125. Other drugs that resulted in the 
causation of bullous FDE were paracetamol (21.42%), cotrimoxazole 
(14.28%), diclofenac (14.28%) carbamazepine (7.14%) and levofloxacin 
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(7.14%). Bullous FDE to cotrimoxazole, diclofenac and paracetamol have 
already been reported across the world75,116,122. 
 The nonpigmenting variant of FDE has been mainly reported to 
occur with pseudoephedrine and phenylpropanolamine106. Few cases of 
NPFDE occurring to paracetamol have been reported so far across the 
world134. In our patient, paracetamol induced nonpigmenting bullous FDE 
on the palms and soles .  
 The previous studies analysing the most frequently involved sites 
have produced varied results. In studies conducted by S. Dhar and 
Mahboob40, extremities were the most common sites affected.  However, 
in a study conducted by Ozkaya Bayazit, genitalia was the most common 
affected site46. In our study, extremities (44.73%) was the most frequent 
site of involvement. The other sites affected, in decreasing order of 
frequencies were  trunk, face, oral mucosa, genitalia  and palms and soles.  
 There was no statistically significant association between FDE 
inducing drugs and FDE sites in our study, as the sample size in most of 
categories was relatively small. However clinical relevance was seen in 
few cluster groups. In all the 5 cases involved, phenytoin induced lesions 
exclusively on the trunk(100%). Ciprofloxacin preferably induced lesions 
on the extremities in 63.63% of cases. Levofloxacin mainly produced 
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lesions on the trunk and face. Cotrimoxazole, as shown in previous 
studies46,50, is capable of inducing  FDE on any site including extremities, 
trunk, face, lips, oral and genital mucosa. Paracetamol was mainly found 
to involve the palms and soles (66.67%).  
 In our study, face involvement was more commonly encountered 
with diclofenac. Lip involvement was mainly seen with drugs like 
cotrimoxazole and diclofenac. In previous studies, lip involvement was 
mainly attributed to cotrimoxazole and pyrazolone group of drugs46,50.  
 In our patients, oral mucosal involvement occurred mainly with 
cotrimoxazole and diclofenac (28.57% each). In a study of FDE on the 
oral mucosa conducted by V.K.Jain, tetracyclines, cotrimoxazole and 
oxyphenbutazone were the most common causative drugs45. Genital 
involvement was mainly caused by cotrimoxazole and fluoroquinolones. 
Genital FDE to fluoroquinolones are very rarely reported in literature. 
FDE exclusively involving the genitalia of 60 male patients were 
investigated by Pandhi R K in 1984190. Tetracyclines, aspirin, metamizole 
and cotrimoxazole were the common etiological agents. Though 
stastistically insignificant, the clinical pattern and distribution of lesions 
in FDE seem to be influenced by the drug in question, and the study of 
pattern may provide useful information in selecting the most likely 
causative drug, especially when the details of the drugs are unknown. 
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 The rate of occurrence of local symptoms at the site of FDE lesions 
was as low as 28% in previous studies40. Our study revealed a rate of 
78.95%, which is quite high. The symptoms appreciated were in the form 
of local itching and burning pain. Systemic symptoms in the form of 
generalised itching, fever with myalgia, headache and abdominal pain 
with nausea were found to be associated in 14.47% of patients. In 
previous studies,the reported incidence of systemic symptoms was as low 
as 1%40. 
 Eosinophilia was seen in  90.79%  of cases which is significantly 
high. It is not known whether patients with eosinophilia are more prone to 
develop FDE . This finding needs to be evaluated  by further studies in 
future. In our study, HIV ELISA was positive in two patients. 
 In the present study, the patch testing done to confirm the causality 
of the offending drugs showed positivity on the lesional skin when 
compared to the nonlesional skin. This finding is concordant with the 
results obtained from other studies190.  
 The willingness to undergo patch testing was obtained only in 64 
patients. Patients who were willing for biopsy were not willing for patch 
testing and vice versa. Nearly half of the patients with FDE to 
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anticonvulsant drugs were unwilling as they had a false belief that their 
seizures could get precipitated as a result of patch testing. 
 In our study, drug patch testing showed  a low rate of positivity 
(32.9%), when compared to few previous studies158,162. This  is attributed 
to the following reasons :  
• The rate of negativity was high among the patients who 
presented with unknown drug details 
•  Many of the patients with negative test results were manual 
labourers and farmers who worked for daily wages. They 
were not able to refrain themselves from strenuous activities. 
•  Positive test results were obtained in 4 patients when the 
reading was   taken on day 4. Not all patients were willing to 
report back on day 4. 
• Patients were hesitant to come back for repeat application 
test or for repeat patch testing with increasing concentration 
of drugs. 
 Biopsy was performed in 43.45% of willing patients. Classical  
histopathological features were seen in both acute and chronic cases. In 
acute cases epidermal spongiosis, basal cell degeneration and 
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inflammatory infiltrares in the upper dermis were more pronounced. 
Dermal melanophages were few. In chronic FDE the infiltrates were less 
dense. The density of melanophages was relatively high. Many patients 
with mucosal FDE and with FDE lesions on the face refused biopsy.  
 As immunohistochemical analysis was expensive, the CD8 marker 
study was performed only in 8 cases (4 acute and 4 chronic). Both acute 
and chronic lesions showed CD8 positivity, though the density of cells 
varied between acute and chronic lesions. Acute lesions  revealed the 
presence of  a few  intraepidermal T-cells close to the basal keratinocytes. 
These findings  clearly reveal  the  persistence of   CD8+ T-cells at the 
sites of FDE, even after resolution of lesions. These resident population 
of  T-cells contribute to the occurrence of lesions at the same site after 
reexposure to the offending drugs.   
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LIMITATIONS OF THE STUDY 
- Approval could not be obtained for oral provocation test, the gold 
standard test done to confirm the causative drug. The confirmation 
of the drugs incriminated in causation of FDE through patch testing 
was not possible in all cases. 
- A statistically significant relation between the offendings drugs and 
drug specific site of involvement could not be established owing to 
small sample size.   
- Regular follow up of cases was not possible. 
- Immunohistochemical analysis to identify CD8+ T-cells in the 
FDE lesions was not done in all cases due to financial limitations.  
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CONCLUSION 
1. The incidence of Fixed Drug Eruption among Dermatology OPD 
attendees from Aug  2008 to Aug 2010 was found to be 0.54%.  
2. The main age group affected was 21 – 30 years.  
3. An almost equal sex incidence. was observed with the male to 
female ratio being 1.23:1. 
4. The incubation period observed during the first and subsequent 
episodes was 13.4 days and 4.6hrs respectively. 
5. The most common offenders were fluoroquinolones especially 
ciprofloxacin seen in 14.5% of cases and levofloxacin in 10.5% of 
cases. The next common offender was cotrimoxazole inducing 
FDE in 11.8% of cases. Nonsteroidal antiinflammatory drugs were 
the causative drugs in 19.73% of cases with diclofenac being the 
main inducer followed by paracetamol. 
6. Classical presentation was seen in 81.57% of cases. The other two 
morphological patterns encountered were Bullous FDE(18.42%) 
and Nonpigmenting FDE(1.33%). 
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7. Multifocal pattern was the most common pattern of distribution of 
lesions. Solitary and generalised patterns were also encountered. 
8. Extremities were the most frequently involved sites seen in 44.73% 
of cases, followed in decreasing order of frequency by trunk, face, 
oral mucosa, genital mucosa, lips and palms and soles. 
9. There was no statistically significant difference between males and 
females regarding the site of involvement . Clinically mucosal 
lesions and lesions on the palms and soles were more commonly 
encountered  in males. Involvement of the lip was commonly seen 
in females. 
10. Though statistically insignificant, clinically significant associations 
were observed regarding drug specific site of involvement. 
Phenytoin induced FDE exclusively on the trunk. Paracetamol was  
observed to induce bullous FDE preferentially on palms and  soles 
Ciprofloxacin induced lesions mainly on the extremities. 
11. The rate of occurrence of associated local and systemic symptoms 
was 78.95% and 14.47% respectively which is relatively high when 
compared to previous studies. 
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12. Drug patch tests done to establish the causality of offending drugs 
revealed positivity in 32.9% of patients. The testing was found to 
be positive when done on lesional skin when compared to 
nonlesional skin. 
13. Histopathological examination of biopsy specimens produced 
consististent findings in all the 33 cases in whom biopsy was 
performed. 
14. Immunohistochemical analysis done using antibodies to CD8 
revealed positivity in both acute and chronic cases, establishing the 
role of these cells in causation of FDE. 
            In the current study, the number of patients observed was less 
when compared to the previous studies. So statistical analysis did not 
reveal any significance regarding the sex specific and drug  specific site 
of involvement. 
            To conclude, in most  cases, fixed drug eruption poses a great 
challenge for the physician to reveal the offending agent, especially when 
patients have a multidrug history and do not remember which drug they 
have taken. Large scale studies investigating the drug specific site of 
involvement in FDE should be carried out in future, so that the offending 
drugs can be identified to some extent based on the site of occurrence of 
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lesions. Regularly updated lists of the most frequent FDE inducers in a 
given community should be made available. 
           Patch testing which is standardised for the diagnosis of allergic 
contact dermatitis is often useful for the diagnosis of offending drugs in 
FDE. As there are differences in the clinical and pathophysiological 
aspects of these two disorders, this technique has to be adapted to the 
study of FDE, so that we can retrieve more specific and sensitive results. 
Subjective symptoms such as local itching and burning can also be 
considered as a positive test result. Oral provocation test should be 
considered only after analysis of the risk- benefit ratio in a patient. 
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PROFORMA 
NAME : 
AGE : 
SEX : 
OCCUPATION : 
OUTPATIENT NUMBER : 
ADDRESS : 
RELEVANT HISTORY : 
1. Nature of the drug - Allopathy / Others 
2. Single or Multiple : 
3. Name of the drug/drugs : 
4. Purpose of drug untake : 
5. Number of episodes - First 
  -  Recurrent(specify number) 
6. Duration of lesions : 
7. Time interval between drug : 
 intake and onset of lesions  
8. Site of occurrence :  
9. Nature of lesions : Reddish flat / Reddish swollen / Fluid 
filled / pigmented 
10. Residual lesion : Pigmenting/nonpigmenting  
11. Ass local symptoms : Itching/Burning/Itching & burning 
12. Ass systemic symptoms : Generalised  itching / Fever / arthralgia / 
Myalgia / Nausea, Vomitting / 
Disorientation  
13. Past history : H/o atopy 
   H/o DM/HT/TB/BA 
14. Personal history                   : 
15. Sexual history                      :  
16. Family history of drug allergy: 
GENERAL EXAMINATION : 
Level of consciousness 
Orientation 
Anemia/Jaundice/Cyanosis 
Body temperature 
Lymph nodes  
Pulse rate 
Blood pressure 
 
SYSTEMIC EXAMINATION : 
CVS                     : 
RS                        : 
ABD                    : 
CNS                     : 
 
DERMATOLOGICAL EXAMINATION : 
SKIN               :    
       Morphological pattern of disease :   
CLASSICAL/BULLOUS/OTHERS 
       Site of lesions  : 
       Number of lesions : 
MUCOSA   : 
PALMS AND SOLES : 
HAIR & NAILS  : 
INVESTIGATIONS : 
  HEMATOLOGICAL : 
 Complete Blood Count           :  Total count 
                                                         Differential count 
                                                         ESR 
 Absolute Eosinophil count  : 
    BLOOD VDRL & HIV ELISA : 
    BIOPSY AND HISTOPATHOLOGICAL EXAMINATION : 
    PATCH TESTING WITH COMMERCIALISED DRUG FORM : 
                    LESIONAL SKIN         : 
                    NONLESIONAL SKIN : 
  IMMUNOHISTOCHEMISTRY(CD8) : 
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FDE - ACUTE LESION (ERYTHEMATOUS PATCH) 
 
FDE - CHRONIC RESIDUAL HYPERPIGMENTED PATCH 
 
BULLOUS FDE : EARLY LESION 
 
 
BULLOUS FDE : FULLY DEVELOPED LESION 
 
 
FDE - SITE OF INVOLVEMENT 
 
  
 FDE Involving Lips and Perioral Area Multifocal FDE involving trunk and  
  Upper Limb 
 
 
  
 Generalised FDE - lesions on trunk  FDE involving extremities 
 and upper limbs 
 
 
 
Solitary FDE in a 8 months old infant  
involving trunk 
FDE ON THE LEFT PALM 
 
 
POLYCYCLIC  FIXED DRUG ERUPTION 
                      
 
 
 
 
 
MUCOSAL FDE 
 
 
 
 
          
 FDE Involving Upper Lip and FDE Involving Upper Lip and 
 Labial Mucosa Hard Palate 
 
 
 
 
 
          
 FDE involving the glans penis Multifocal FDE with Vulval  Lesions 
 
 
PATCH TEST - POSITIVE FOR CIPROFLOXACIN 
 
 
PATCH TEST - POSITIVE FOR DOXYCYCLINE 
 
 
HISTOPATHOLOGY OF FDE 
 
 
H & E section of acute FDE  showing moderate acanthosis, 
basal cell degeneration, necrotic keratinocytes, pigment 
incontinence and dilated vessels 
 
 
 
H & E section of chronic FDE showing foci of basal cell 
degeneration and dense melanophages in the upper dermis 
 
 
 
 
 
H & E Section of BULLOUS FDE - Subepidermal bulla 
with inflammatory infiltrates in the upper dermis 
 
 
 
 
HPE OFGENITAL FDE (40x view) with Irregular acanthosis, 
mild spongiosis, basal cell degeneration, necrotic 
keratinocytes subepidermal infiltrates and dilated 
dermal blood vessels 
 
 
HISTOPATHOLOGY OF FDE 
 
 
H & E section (40x view) 
dyskeratotic cells 
 
H & E section (40x view) 
perivascular infiltrate 
 
H & E section (40x view) 
extravasated RBCs 
 
IMMUNOHISTOCHEMISTRY OF FDE (ACUTE LESION) 
 
IHC(10x view) of acute FDE lesion showing intraepidermal CD8+ T-cells in 
the basal layer and dense collection of CD8+ T-cells in the upper dermis. 
 
 
 
 
IHC (40x view) of acute FDE lesion showing dense collection of  
CD8 + T-cells in the upper dermis 
 
IMMUNOHISTOCHEMISTRY OF FDE (CHRONIC LESION) 
 
IHC (10x view) of chronic lesion showing diffuse sparse collection of  
CD8+T-cells in the upper dermis 
 
 
 
IHC (40x view) of chronic FDE lesion showing sparse CD8+T-cells 
